Kalaris Therapeutics (KLRS) Competitors $4.93 -0.17 (-3.33%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KLRS vs. ALTS, CGC, ETHZ, CAPR, ALDX, LYEL, MREO, NMRA, ALEC, and GALTShould you be buying Kalaris Therapeutics stock or one of its competitors? The main competitors of Kalaris Therapeutics include ALT5 Sigma (ALTS), Canopy Growth (CGC), Flag Ship Acquisition (ETHZ), Capricor Therapeutics (CAPR), Aldeyra Therapeutics (ALDX), Lyell Immunopharma (LYEL), Mereo BioPharma Group (MREO), Neumora Therapeutics (NMRA), Alector (ALEC), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. Kalaris Therapeutics vs. Its Competitors ALT5 Sigma Canopy Growth Flag Ship Acquisition Capricor Therapeutics Aldeyra Therapeutics Lyell Immunopharma Mereo BioPharma Group Neumora Therapeutics Alector Galectin Therapeutics Kalaris Therapeutics (NASDAQ:KLRS) and ALT5 Sigma (NASDAQ:ALTS) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends. Which has higher valuation and earnings, KLRS or ALTS? ALT5 Sigma has higher revenue and earnings than Kalaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalaris TherapeuticsN/AN/A-$58.77MN/AN/AALT5 Sigma$22.26M13.53-$6.24MN/AN/A Does the media refer more to KLRS or ALTS? In the previous week, ALT5 Sigma had 4 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 8 mentions for ALT5 Sigma and 4 mentions for Kalaris Therapeutics. ALT5 Sigma's average media sentiment score of 0.96 beat Kalaris Therapeutics' score of 0.79 indicating that ALT5 Sigma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALT5 Sigma 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in KLRS or ALTS? 66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 75.0% of Kalaris Therapeutics shares are held by insiders. Comparatively, 0.7% of ALT5 Sigma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer KLRS or ALTS? Kalaris Therapeutics currently has a consensus target price of $3.00, indicating a potential downside of 39.15%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Kalaris Therapeutics is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is KLRS or ALTS more profitable? Kalaris Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -74.89%. Kalaris Therapeutics' return on equity of -81.02% beat ALT5 Sigma's return on equity.Company Net Margins Return on Equity Return on Assets Kalaris TherapeuticsN/A -81.02% -65.15% ALT5 Sigma -74.89%-179.27%-16.28% Which has more risk and volatility, KLRS or ALTS? Kalaris Therapeutics has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, ALT5 Sigma has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. SummaryKalaris Therapeutics beats ALT5 Sigma on 7 of the 13 factors compared between the two stocks. Get Kalaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLRS vs. The Competition Export to ExcelMetricKalaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.19M$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E RatioN/A22.9285.4427.36Price / SalesN/A270.00515.26195.91Price / CashN/A46.9537.5761.53Price / Book0.2210.5512.426.82Net Income-$58.77M-$52.58M$3.32B$276.89M7 Day Performance-25.19%1.09%1.01%0.27%1 Month Performance32.88%16.09%10.75%8.31%1 Year PerformanceN/A18.41%76.20%35.60% Kalaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLRSKalaris Therapeutics1.3571 of 5 stars$4.93-3.3%$3.00-39.1%N/A$92.19MN/A0.00110News CoverageALTSALT5 Sigma0.4861 of 5 stars$2.63-9.0%N/A+39.9%$329.24M$22.26M0.00170News CoverageCGCCanopy Growth0.8176 of 5 stars$1.37-17.0%N/A-67.5%$328.59M$225.65M-0.453,150Positive NewsETHZFlag Ship AcquisitionN/A$1.98-9.6%N/AN/A$325.57MN/A-0.137Stock SplitGap DownCAPRCapricor Therapeutics1.9312 of 5 stars$7.09-7.0%$22.25+213.8%-65.8%$324.13M$13.39M-4.32101ALDXAldeyra Therapeutics1.8144 of 5 stars$5.39-4.9%$9.50+76.3%-1.8%$322.84MN/A-6.3410LYELLyell Immunopharma1.4766 of 5 stars$16.51-12.5%$15.00-9.1%-29.2%$317.17M$60K-0.68270Positive NewsMREOMereo BioPharma Group2.3128 of 5 stars$1.96-6.7%$7.40+277.6%-56.2%$311.64M$10M-28.0040NMRANeumora Therapeutics2.1061 of 5 stars$1.89-3.1%$7.14+277.9%-88.5%$306.08MN/A-1.20108News CoverageALECAlector3.5217 of 5 stars$3.02-3.8%$4.17+38.0%-39.0%$305.66M$100.56M-2.60270GALTGalectin Therapeutics1.1911 of 5 stars$4.72-0.6%$6.00+27.1%+88.6%$302.36MN/A-7.389 Related Companies and Tools Related Companies ALTS Competitors CGC Competitors ETHZ Competitors CAPR Competitors ALDX Competitors LYEL Competitors MREO Competitors NMRA Competitors ALEC Competitors GALT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLRS) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
